CASTLE BIOSCIENCES INC (CSTL)
Health Care · NASDAQ
Castle Biosciences develops proprietary gene expression and spatialomics diagnostic tests to guide treatment decisions in dermatologic cancers, Barrett's esophagus, and atopic dermatitis.
What CASTLE BIOSCIENCES INC does
Castle Biosciences is a molecular diagnostics company that develops and offers multi-analyte assay tests to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The company's tests use gene expression profiling and other molecular technologies to provide personalized, clinically actionable information to guide treatment decisions and patient management. Its core revenue comes from tissue-based tests that characterize individual patient biology to inform clinical care.
Themes: ["Melanoma diagnosis and risk stratification","Barrett's esophagus screening and progression risk","Atopic dermatitis treatment selection","Uveal melanoma diagnosis","Molecular diagnostics","Precision medicine / personalized diagnostics","Gene expression profiling","Cancer risk stratification"]
Fundamentals
- Price$24.56 as of 2026-07-09 close
- Market cap$746M as of 2026-07-10
- 1-year return+22.1% as of 2026-07-09 close
- Net margin-3.8% as of 2026-07-10
- Gross margin+77.9% as of 2026-07-10
- ROE-2.8% as of 2026-07-10
- Debt / equity0.03 as of 2026-07-10
- Revenue growth (YoY)-2.1% as of 2026-07-10
- Revenue CAGR (3y)+35.9% SEC XBRL
- Beta1.02 as of 2026-07-10
Key risks (from latest filing)
["Declining revenue growth (-2.06% YoY) and ongoing unprofitability (-3.78% net margin) despite operational efforts, indicating challenges in commercial adoption and reimbursement","Dependence on continued clinical evidence generation, guideline inclusion, and appropriate reimbursement to maintain clinician adoption—failure to secure Medicare/insurance coverage or maintain coverage could significantly impact revenue","New product launches (AdvanceAD-Tx commenced limited launch November 2025; TissueCypher expansion via Capsulomics acquisition) require significant clinical validation and commercialization investment with uncertain near-term revenue contribution, while company burns through cash (Q1 2026 ending cash $63.8M vs $116.7M at year-end 2025)"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.